Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041167 | 1.00 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL27170334 | 1.00 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL28136505 | 0.98 | KMT2A (0.61) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL28135732 | 0.98 | KMT2A (0.61) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL3759118 | 0.91 | SQLE (0.50) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL23802597 | 0.79 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| Squalene SCHEMBL4444267 | 0.79 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| Squalene SCHEMBL21823197 | 0.79 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL21639794 | 0.79 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL8013144 | 0.79 | KMT2A (1.00) | KMT2ASQLEALOX15MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4137142-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | Purple Mundo, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | SC LABORATORIES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-7252845-B2 | Synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga | FERROSAN A/S (DK) | 2007-08-07 | — | — | US | claimed |
| US-20230404944-A1 | CANNABINOID ENCAPSULATION TECHNOLOGY | Zelira Therapeutics Operations Pty Ltd (AU) | 2023-12-21 | — | — | US | disclosed |
| US-11820847-B2 | Copolymer, method of preparing the same, and rubber composition including the same | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20230364052-A1 | COMPOSITION AND METHOD FOR TREATING AUTISM | Zelira Therapeutics Operations Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-11779562-B2 | Cannabis composition | Zelira Therapeutics Operations Pty Ltd (AU) | 2023-10-10 | — | — | US | disclosed |
| US-11752184-B2 | Bioactive concentrates and uses thereof | PURPLE MUNDO, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230270808-A1 | SLEEP DISORDER COMPOSITIONS AND TREATMENTS THEREOF | Zelira Therapeutics Operations Pty Ltd (AU) | 2023-08-31 | — | — | US | disclosed |
| US-20230218566-A1 | Composition and Method for Treating Chronic Pain | Zelira Therapeutics Operations Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230192934-A1 | COPOLYMER, METHOD OF PREPARING THE SAME, AND RUBBER COMPOSITION INCLUDING THE SAME | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20180296498-A1 | MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE | International Bioceutical Co. LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20180208946-A1 | METHOD FOR PRODUCING FRAGRANT ALCOHOLS | FIRMENICH SA (CH) | 2018-07-26 | — | — | US | disclosed |
| US-9909145-B2 | Method for producing fragrant alcohols | FIRMENICH SA (CH) | 2018-03-06 | — | — | US | disclosed |
| CN-105028186-B | Method for improving aroma of citrus fruits | 华中农业大学 | 2017-02-22 | — | — | CN | disclosed |
| US-20160215301-A1 | METHOD FOR PRODUCING FRAGRANT ALCOHOLS | FIRMENICH SA (CH) | 2016-07-28 | — | — | US | disclosed |
| CN-105555959-A | Process for producing aromatic alcohols | FIRMENICH & CIE | 2016-05-04 | — | — | CN | disclosed |
| CN-105028186-A | Method for improving aroma of citrus fruits | UNIV HUAZHONG AGRICULTURAL | 2015-11-11 | — | — | CN | disclosed |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | SC LABORATORIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| JP-2004091742-A | KEY LIME FRAGRANT MATERIAL AND KEY LIME FRAGRANT MATERIAL-CONTAINING FOOD | SANEI GEN FFI INC | 2004-03-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404944-A1 | CANNABINOID ENCAPSULATION TECHNOLOGY | CNR2, CNR1, GPR18 | KMT2A 2219/4885SQLE 2203/4885ALOX15 484/4885 |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | CNR2, CNR1, CDIPT | KMT2A 4214/4885SQLE 114/4885ALOX15 28/4885 |
| US-11752184-B2 | Bioactive concentrates and uses thereof | CNR2, CNR1, CDIPT | KMT2A 4214/4885SQLE 114/4885ALOX15 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.